Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389721 · ClinicalTrials.gov registry record
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
A clinical trial of Chemotherapy-induced Peripheral Neuropathy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06389721: Recruiting study of Chemotherapy-induced Peripheral Neuropathy, sponsored by M.D. Anderson Cancer Center.
NCT06389721 is a study of Chemotherapy-induced Peripheral Neuropathy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06389721, a study of Chemotherapy-induced Peripheral Neuropathy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN). Cohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clBCI) to see if can help to prevent pain due to CIPN.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Electroencephalogram (EEG)
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-07-16 |
| Est. Completion | 2027-01-31 |
What NCT06389721 shows while recruiting
NCT06389721 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Electroencephalogram (EEG) is the first listed.
NCT06389721 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06389721 about?
NCT06389721 is a clinical study titled "Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy". Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN). Cohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stim...
What is the current status of trial NCT06389721?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2024-07-16. Estimated completion is 2027-01-31.
What conditions does trial NCT06389721 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT06389721?
The interventions under investigation include: Electroencephalogram (EEG) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06389721?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06389721 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06389721's enrollment target sits among peer trials
45 17th of 29 higher than 13 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression for CIPN
RECRUITING · NA
-
VGAIT for Chemotherapy-induced Peripheral Neuropathy
RECRUITING · NA
-
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
RECRUITING · NA
-
Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · NA
-
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · NA
-
International CIPN Assessment and Validation Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI